Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study

Ophthalmology

Volumn 122, Issue 11, 2015, Pages 2303-2310

  Kuroda, Yoshimasa ^a   Yamashiro, Kenji ^a   Miyake, Masahiro ^a   Yoshikawa, Munemitsu ^a   Nakanishi, Hideo ^a   Oishi, Akio ^a   Tamura, Hiroshi ^a   Ooto, Sotaro ^a   Tsujikawa, Akitaka ^b   Yoshimura, Nagahisa ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; ARMS2 PROTEIN, HUMAN; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H, HUMAN; PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL EVALUATION; COHORT ANALYSIS; CONTACT LENS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INTRAOCULAR PRESSURE; LASER COAGULATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SLIT LAMP; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; GENETICS; GENOTYPING TECHNIQUE; INTRAVITREAL DRUG ADMINISTRATION; PHYSIOLOGY; RETREATMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; COMPLEMENT FACTOR H; FEMALE; GENOTYPING TECHNIQUES; HUMANS; INTRAVITREAL INJECTIONS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; RANIBIZUMAB; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84939559652     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.06.053     Document Type: Article

References (40)

1. D.S. Friedman, B.J. O'Colmain, B. Munoz, and et al. Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
2. R.N. Frank, R.H. Amin, D. Eliott, and et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes Am J Ophthalmol 122 1996 393 403
3. P.F. Lopez, B.D. Sippy, H.M. Lambert, and et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes Invest Ophthalmol Vis Sci 37 1996 855 868
4. A. Otani, H. Takagi, H. Oh, and et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes Microvasc Res 64 2002 162 169
5. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
6. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
7. C.D. Regillo, D.M. Brown, P. Abraham, and et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
8. F.G. Holz, W. Amoaku, J. Donate, and et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study Ophthalmology 118 2011 663 671
9. U. Schmidt-Erfurth, B. Eldem, R. Guymer, and et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 2011 831 839
10. A.E. Fung, G.A. Lalwani, P.J. Rosenfeld, and et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
11. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung, and et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58.e1
12. D.F. Martin, M.G. Maguire, S.L. Fine, and et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
13. S. Rofagha, R.B. Bhisitkul, D.S. Boyer, and et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 2013 2292 2299
14. R. Spaide Ranibizumab according to need: a treatment for age-related macular degeneration Am J Ophthalmol 143 2007 679 680
15. M. Engelbert, S.A. Zweifel, and K.B. Freund "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation Retina 29 2009 1424 1431
16. O.P. Gupta, G. Shienbaum, A.H. Patel, and et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact Ophthalmology 117 2010 2134 2140
17. H. Oubraham, S.Y. Cohen, S. Samimi, and et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 2011 26 30
18. A. Oishi, M. Mandai, A. Nishida, and et al. Remission and dropout rate of anti-VEGF therapy for age-related macular degeneration Eur J Ophthalmol 21 2011 777 782
19. I. Maruko, T. Iida, M. Saito, and et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients Am J Ophthalmol 144 2007 15 22
20. J.T. Holladay Proper method for calculating average visual acuity J Refract Surg 13 1997 388 391
21. H. Koizumi, T. Yamagishi, T. Yamazaki, and S. Kinoshita Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy Br J Ophthalmol 95 2011 1555 1559
22. K. Yamashiro, K. Tomita, A. Tsujikawa, and et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment Am J Ophthalmol 154 2012 125 136
23. T. Hikichi, M. Higuchi, T. Matsushita, and et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients Am J Ophthalmol 154 2012 117 124.e1
24. H. Koizumi, T. Yamagishi, T. Yamazaki, and S. Kinoshita Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability Am J Ophthalmol 155 2013 305 313.e1
25. J. Tian, X. Qin, K. Fang, and et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population Pharmacogenomics 13 2012 779 787
26. F. Abedi, S. Wickremasinghe, A.J. Richardson, and et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration Ophthalmology 120 2013 1641 1648
27. S.J. Teper, A. Nowinska, J. Pilat, and et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration Mol Vis 16 2010 2598 2604
28. B. Kloeckener-Gruissem, D. Barthelmes, S. Labs, and et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD Invest Ophthalmol Vis Sci 52 2011 4694 4702
29. A. Orlin, D. Hadley, W. Chang, and et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration Retina 32 2012 4 9
30. M. Hata, A. Tsujikawa, M. Miyake, and et al. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy Graefes Arch Clin Exp Ophthalmol 253 2015 221 227
31. S.A. Hagstrom, G.S. Ying, G.J. Pauer, and et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT) Ophthalmology 120 2013 593 599
32. H.K. Kang, M.H. Yoon, D.H. Lee, and H.S. Chin Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population Korean J Ophthalmol 26 2012 414 422
33. M. Menghini, B. Kloeckener-Gruissem, J. Fleischhauer, and et al. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration PLoS One 7 2012 e42014
34. I. Mantel, A. Deli, K. Iglesias, and A. Ambresin Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 251 2013 697 704
35. K. Yamashiro, A. Tsujikawa, A. Nishida, and et al. Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy Jpn J Ophthalmol 52 2008 457 462
36. W.M. Chan, D.S. Lam, T.Y. Lai, and et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level Br J Ophthalmol 87 2003 1453 1458
37. L. Xu, T. Lu, L. Tuomi, and et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach Invest Ophthalmol Vis Sci 54 2013 1616 1624
38. A. Koh, W.K. Lee, L.J. Chen, and et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina 32 2012 1453 1464
39. R. Mathew, M. Richardson, and S. Sivaprasad Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab Am J Ophthalmol 155 2013 720 726 6.e1
40. C. Simader, M. Ritter, M. Bolz, and et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration Ophthalmology 121 2014 1237 1245